Society for Immunotherapy of Cancer

SITC 2016

Award Ceremony

November 12, 2016
6:15 p.m.

As of October 11, 2016
31st Award Ceremony
Saturday, November 12, 2016
Maryland Ballroom 4-6, BD • 6:15 – 6:45 p.m.

Welcome
Howard L. Kaufman, MD, FACS – SITC President

Presentation of Awards

2016 Connect-a-Colleague Top Referrer
2016 Young Investigator Travel Awards
• SITC Abstract Travel Awards
• SITC Presidential Travel Awards
2016 Journal for ImmunoTherapy of Cancer Best Paper Awards
• JITC Best Basic Science Research Paper
• JITC Best Clinical/Translational Research Paper
2016 Cancer Immunotherapy Fellowship Awards
• SITC-AstraZeneca Cancer Immunotherapy Clinical Fellowship in Non-Small Cell Lung Cancer (NSCLC) Award
• SITC-Bristol-Myers Squibb Cancer Immunotherapy Translational Fellowship Award
• SITC-EMD Serono Cancer Immunotherapy Clinical Fellowship Award
• SITC-Genentech Postdoctoral Cancer Immunotherapy Basic Fellowship in Related Biomarkers Award
• SITC-Genentech Postdoctoral Cancer Immunotherapy Clinical Fellowship in Related Biomarkers or Mechanism of Action (MOA) Award
2016 Collaborative Awards
• NCI Immunotherapy Fellowship
• SITC-MRA Young Investigator Award
2016 Richard V. Smalley, MD Memorial Lectureship Award
2016 SITC Presidential Award

The celebration continues immediately following tonight’s Award Ceremony:

Poster Reception
Prince George’s Exhibition Hall AB • 6:45 – 8:00 p.m.

The CheckPoints Party
Maryland Ballroom • 8:30 – 11:30 p.m.
The Society for Immunotherapy of Cancer’s (SITC) 31st Award Ceremony celebrates the achievements of current and future leaders in the cancer immunotherapy field.

The work of these dedicated individuals that include young investigators and luminaries in the field seeks to propel the field forward and build a solid foundation for future advances and soon, a cure.

About the Award Ceremony

About the Forward Fund

The future of cancer immunotherapy lies in research and education, primarily by early career scientists. The Forward Fund was established to stimulate the future of the science, development and application of cancer immunotherapy through financially supporting its education and research.

The Forward Fund provides grants that will help attract the brightest young minds in cancer and/or immunology research to the cancer immunotherapy domain. It informs those outside of the cancer immunotherapy field about the huge promise of this modality, which offers the potential of creating long-term remissions and/or prolongation of survival for people suffering from an expanding array of advanced cancer types.

The Forward Fund relies on the generosity of our members, foundations, industry partners and others to make these awards possible. Please contribute to ensure that we can keep providing these awards and ensure the future success of immunotherapy.

The Forward Fund is proud to financially support the Richard V. Smalley, MD Memorial Lectureship Award, the Presidential Award, Young Investigator Travel Awards, Named Postdoctoral Fellowships, as well as collaborative awards and fellowships.
Launched in November 2015, The Connect-A-Colleague campaign is designed to encourage members to personally reach out and invite potential members to join the society. An online tool was created for members to refer multiple potential members at a time. New members are also encouraged to indicate SITC members who referred them for membership. Nearly 200 SITC members have participated in the campaign, referring 34% of all new members. This year’s recipient has personally referred nearly half of the members in SITC’s new member category: Nurse and Physician Extender.

Laura S. Wood, RN, MSN, OCN
Cleveland Clinic Taussig Cancer Institute
2016 SITC Abstract Travel Awards

Created in 2007, the SITC Abstract Travel Award highlights promising young investigators who submitted high-scoring abstracts to the SITC Annual Meeting, based on the quality of their research and potential to advance the field. In 2016, 31 young investigators will receive travel awards in the abstract travel and presidential travel categories.

Ephraim A. Ansa-Addo, PhD, MSB
Medical University of South Carolina

Natalie Collins, MD, PhD
Dana-Farber Cancer Institute

Cristina Bergamaschi, PhD
National Cancer Institute

Cara Haymaker, PhD
University of Texas MD Anderson Cancer Center

Tullia C. Bruno, PhD
University of Pittsburgh

Tyler Hulett
Providence Cancer Center

Fanny Chapelin, MS
University of California San Diego

Michael Klichinsky, PharmD
Center for Cellular Immunotherapies
University of Pennsylvania
Daniel Landi, MD
Center for Gene & Cell Therapy
Baylor College of Medicine

Alessandra Metelli
Medical University of South Carolina

Thomas Mace, PhD
Ohio State University

Nicholas Minutolo
University of Pennsylvania

Kathleen M. Mahoney, MD, PhD
Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute

John Mullinax, MD
H. Lee Moffitt Cancer Center

Adam W. Mailloux, PhD
H. Lee Moffitt Cancer Center

Sukhmani K. Padda, MD
Stanford University School of Medicine

Melinda Mata, PhD
Center for Gene & Cell Therapy
Baylor College of Medicine

Jonathan Schoenfeld, MD, MPH
Brigham and Women’s Hospital Dana-Farber Cancer Center
2016 SITC Abstract Travel Awards
(continued)

Tala Shekarian
UCBL1
Centre Léon Bérard

Marie-Nicole Theodoraki, MD
University of Pittsburgh

John-William Sidhom
Johns Hopkins University
School of Medicine

Katy Tsai, MD
University of California
San Francisco

Stefani Spranger, PhD
University of Chicago

Claire Vanpouille-Box, PhD
Weill Cornell Medicine

Randy F. Sweis, MD
University of Chicago

Jessica Wenthe
Uppsala University

Jason B. Williams
University of Chicago
2016 SITC Presidential Travel Awards

These recipients’ abstracts were the top scoring among those submitted for the Annual Meeting by young investigators based on quality of research, excellence in results and methods, and the potential of their work to advance the field. Of the four recipients pictured below, one will be selected to receive the SITC Presidential Travel Award.

Established in 1991, the SITC Presidential Travel Award is the most prestigious Young Investigator Award and recognizes the young investigator deemed to have the most outstanding oral abstract presentation among those delivered in the Presidential Session of the SITC Annual Meeting. The recipient will be announced at the end of tonight’s ceremony.

Jonathan Peled, MD, PhD
Memorial Sloan Kettering Cancer Center

David Woods, PhD
NYU Langone Medical Center

Nicole Scharping
University of Pittsburgh

Roberta Zappasodi, PhD
Memorial Sloan Kettering Cancer Center
2016 Journal for ImmunoTherapy of Cancer Best Paper Awards

The JITC Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts. Papers published in the last 12 months authored by SITC members were eligible for nomination for this award.

JITC Best Basic Science Research Paper

Articles nominated in this category present innovative research in basic medical sciences that have a direct relevance to future research in clinical medicine.

Presented to First Authors:

Katherine Woods, PhD
Olivia Newton-John Cancer Research Institute

“Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma”

Katherine Woods, Ashley J. Knights, Matthew Anaka, Ralf B. Schittenhelm, Anthony W. Purcell, Andreas Behren and Jonathan Cebon
Journal for ImmunoTherapy of Cancer 2016, 4:10 (16 February 2016)
JITC Best Clinical/Translational Research Paper

Papers in this category present clinical research that has a clear potential to optimize patient care, with particular emphasis on high quality randomized controlled trials, novel combination treatments, therapies, novel diagnostic or prognostic insights and new insights into mechanism of action.

Presented to First Authors:

Zipei Feng
Oregon Health & Science University

Sachin Puri, PhD
MedImmune

“Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma”

Zipei Feng, Sachin Puri, Tarsem Moudgil, William Wood, Clifford C. Hoyt, Chichung Wang, Walter J. Urba, Brendan D. Curti, Carlo B. Bifulco and Bernard A. Fox
2016 Cancer Immunotherapy Fellowship Awards

SITC is proud to announce the recipients of the SITC 2016 Cancer Immunotherapy Fellowship Awards. The Fellowship Award program was established through SITC’s Forward Fund to support the development of young investigators in the field in order to cultivate the next generation of cancer immunotherapy experts.

SITC would like to thank AstraZeneca, Bristol-Myers Squibb, EMD-Serono, Genentech, NCI Center for Cancer Research, and the Melanoma Research Alliance (MRA) who helped to make these awards possible.

SITC-AstraZeneca Cancer Immunotherapy Clinical Fellowship in Non-Small Cell Lung Cancer (NSCLC) Recipient

Miguel F. Sanmamed, MD, PhD
Yale University


SITC-Bristol-Myers Squibb Cancer Immunotherapy Translational Fellowship Recipient

Benjamin Izar, MD, PhD
Dana-Farber Cancer Institute

“Dissecting the role of tissue-specific anti-tumor immunity following PD-1 blockade”
SITC-EMD Serono Cancer Immunotherapy Clinical Fellowship Recipient

Eric L. Smith, MD, PhD
Memorial Sloan Kettering Cancer Center

“Investigating and manipulating the interplay between the tumor microenvironment and Chimeric Antigen Receptor T cell therapy to generate durable remissions in multiple myeloma”

SITC-Genentech Postdoctoral Cancer Immunotherapy Basic Fellowship in Related Biomarkers Recipient

Ada G. Blidner, MSc, PhD
Immunopathology Laboratory, Institute of Biology and Experimental Medicine, Argentina

“Unraveling the role of the galectin-1/glycan axis in T cell exhaustion and resistance to cancer immunotherapy”

SITC-Genentech Postdoctoral Cancer Immunotherapy Clinical Fellowship in Related Biomarkers/Mechanism of Action (MOA) Recipient

Claire F. Friedman, MD
Memorial Sloan Kettering Cancer Center

“The tumor immune microenvironment and response to CTLA-4 blockade in PD-1 refractory metastatic melanoma”
2016 Collaborative Awards

NCI Immunotherapy Fellowship

This award, co-sponsored by the NCI Center for Cancer Research and SITC and made possible in part by an educational grant from EMD-Serono, provided a young investigator with an opportunity to further their education and experience in the field of cancer immunotherapy.

The fellow will have exposure to multiple clinical immunotherapeutic approaches, and also to key opinion leaders in the field of clinical immunotherapy during this one year program at the CCR in Bethesda, MD.

Julius Strauss, MD
National Cancer Institute,
National Institutes of Health

SITC-MRA Young Investigator Award

Developed in collaboration with the Melanoma Research Alliance (MRA), the SITC-MRA Young Investigator Award aims to attract early career scientists with novel ideas into melanoma research, thereby recruiting and supporting the next generation of melanoma leaders.

Ping-Chih Ho, PhD
University of Lausanne, Switzerland

“Immunometabolic editing facilitates immune evasion in melanomas”
Announcing the 2017 Cancer Immunotherapy Fellowship Opportunities

SITC is proud to announce that we will be offering the following fellowships in 2017, made possible through the generosity and partnership of the organizations outlined below. More information about these awards, including the submission timeline, criteria and deadlines, will be released in December 2016 on the SITC website. Submission site will open at the end of January 2017.

SITC’S Holbrook Kohrt, MD, PhD Cancer Immunotherapy Translational Memorial Fellowship Award (Sponsored by Genentech)

This named cancer immunotherapy translational memorial fellowship award is named after Holbrook Kohrt, MD, PhD, assistant professor at the Stanford University School of Medicine, renowned for his clinical trials research examining novel immunologic approaches and his translational research on novel therapies to enhance anti-tumor immunity.

SITC-Merck Cancer Immunotherapy in Lung Cancer Clinical Fellowship Award

This named cancer immunotherapy clinical fellowship award will help to support the development of the next generation of immunotherapy experts who have a vested interest in furthering the clinical research and translation of cancer immunotherapy in lung cancer.
2016 Richard V. Smalley, MD Memorial Lectureship Award

About the Smalley Award

As one of the society’s charter members, Richard V. Smalley, MD was an integral part of the SITC fabric from its inception. Dr. Smalley served on the original Board of Directors from 1984-1990, where he also served as the society’s third President from 1988 – 1990, leading the society through some of its most formative years. SITC’s success is due in large part to the consummate dedication and leadership of Richard V. Smalley, MD.

Established in 2005, the Richard V. Smalley, MD Memorial Lectureship Award is presented each year to a luminary in the field that has significantly contributed to the advancement of cancer immunotherapy research. The award serves to honor those that have been pioneers in their work and have made a notable impact worthy of high regard and recognition by their peers.

SITC is proud to recognize Suzanne L. Topalian, MD; Professor, Surgery and Oncology, Johns Hopkins University School of Medicine; Director, Melanoma Program, Sidney Kimmel Comprehensive Cancer Center as the 2016 Richard V. Smalley, MD Memorial Lectureship Award recipient.
About Dr. Topalian

Dr. Topalian received her medical degree from the Tufts University School of Medicine and completed a general surgery residency at the Thomas Jefferson University Hospital in Philadelphia. She was a research fellow and subsequently a Senior Investigator in the National Cancer Institute, National Institutes of Health. She joined the Johns Hopkins faculty in 2006 to direct the Melanoma Program in the Kimmel Cancer Center. Dr. Topalian is a physician-scientist whose studies of human antitumor immunity have provided a foundation for the translational development of cancer vaccines, adoptive T cell transfer, and immunomodulatory monoclonal antibodies. Her current research focuses on manipulating immune checkpoints such as PD-1 in cancer therapy, and discovering biomarkers predicting clinical outcomes.

Honors & Affiliations

Dr. Suzanne Topalian was named one of Nature’s 10 in 2014, and received the Karnofsky Award from the American Society of Clinical Oncology in 2015. Her work has opened new avenues of scientific investigation in cancer immunology and immunotherapy, and has established this modality as a treatment approach in oncology.
SITC’S Cancer Immunotherapy Sparkathon Ignites Innovation!

SITC’s Sparkathon – Emerging Leaders, Igniting Innovation – is an initiative that is cool, inventive and an exciting opportunity for early career professionals looking for ways to contribute to the larger priorities for the field and society. Through an application process, a group of 30 emerging leaders will explore the critical hurdles that have been challenging the cancer immunotherapy field for years. Once projects have been determined, teams will embark on formulating plans to solve these major issues. Participants will have access to leadership development experts to help develop the proposals to ensure the potential for successful implementation. Projects will be presented to a panel of SITC leaders who will select the top proposals for implementation.
Matching Donation Challenge

Making the Sparkathon even more thrilling is how it is funded. All donations made to SITC's Forward Fund will be doubled by an anonymous foundation. SITC has been challenged to raise $300,000 over the next two years ($150,000 per year).

Stop by the On Site Materials and Merchandise desk to make a donation or visit the website below to double your impact.

If SITC reaches the goal, it means $600,000 will help create a unique opportunity for SITC’s early career professionals to tackle the biggest hurdles challenging the future of cancer immunotherapy. Consider making a pledge or contribution to the Forward Fund – make twice the impact and a lasting difference for the future of cancer immunotherapy.

Make a donation at:
bit.ly/Sparkathon

As a 501 (c) (3) organization, donations made to SITC are tax deductible as a charitable contribution to the extent allowed by law.